Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/54354
Title: | Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial |
Authors: | |
Filiation: | Servicio de Oncología. Hospital Universitario de Fuenlabrada |
Keywords: | |
Mesh: | |
Decs: | |
Issue Date: | 2020 |
Citation: | Breast Cancer Res.2020 11;(22)1:124 |
Abstract: | Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. |
PMID: | 33176887 |
URI: | https://hdl.handle.net/20.500.12530/54354 |
Rights: | info:eu-repo/semantics/openAccess |
Appears in Collections: | Hospitales > H. U. de Fuenlabrada > Artículos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Breast Cancer Research.pdf | 1.39 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License